Skip to content
Iobenguane i 131
Azedra (iobenguane i 131) is a small molecule pharmaceutical. Iobenguane i 131 was first approved as Iobenguane sulfate i 131 on 1994-03-25.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Azedra
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Iobenguane i-131
Tradename
Company
Number
Date
Products
AZEDRAProgenics PharmaceuticalsN-209607 RX2018-07-30
1 products, RLD, RS
Iobenguane sulfate i-131
Tradename
Company
Number
Date
Products
IOBENGUANE SULFATE I 131Sun Pharmaceutical IndustriesN-020084 DISCN1994-03-25
1 products
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
azedraNew Drug Application2019-03-06
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration
Code
IOBENGUANE I-131, AZEDRA, PROGENICS PHARMS INC
2025-07-30ODE-204
Patent Expiration
No data
ATC Codes
V: Various drug classes in atc
V09: Diagnostic radiopharmaceuticals
V09I: Tumour detection radiopharmaceuticals
V09IX: Other diagnostic radiopharmaceuticals for tumour detection in atc
V09IX02: Iobenguane (131i)
V10: Therapeutic radiopharmaceuticals
V10X: Other therapeutic radiopharmaceuticals in atc
V10XA: Iodine (131i) compounds
V10XA02: Iobenguane (131i)
HCPCS
No data
Clinical
Clinical Trials
58 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Heart failureD006333EFO_0003144I50314
Left ventricular dysfunctionD01848711
Parkinsonian disordersD020734HP_000130011
Lewy body diseaseD020961EFO_0006792G31.8311
DementiaD003704F0311
Rem sleep behavior disorderD020187EFO_0007462G47.5211
Cognitive dysfunctionD060825G31.8411
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeuroblastomaD009447EFO_0000621101441036
PheochromocytomaD010673352716
ParagangliomaD010235331410
Neuroendocrine tumorsD018358EFO_1001901D3A.822115
GanglioneuroblastomaD0183051113
Carcinoid tumorD002276D3A.00112
Papillary thyroid cancerD00007727311
Neoplasm metastasisD009362EFO_000970811
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C8011
Neuroectodermal tumorsD01759911
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
RetinoblastomaD01217511
Thyroid neoplasmsD013964EFO_000384111
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
ObesityD009765EFO_0001073E66.911
Type 2 diabetes mellitusD003924EFO_0001360E1111
Takotsubo cardiomyopathyD054549EFO_1002000I51.8111
Ventricular tachycardiaD017180I47.211
Cardiac arrhythmiasD001145EFO_0004269I49.911
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameIOBENGUANE I 131
INNiobenguane (131i)
Description
Iobenguane (131I) is an organoiodine compound.
Classification
Small molecule
Drug classiodine-containing contrast media
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
N=C(N)NCc1cccc([131I])c1
Identifiers
PDB
CAS-ID77679-27-7
RxCUI
ChEMBL IDCHEMBL1615779
ChEBI ID
PubChem CID71184
DrugBankDB06704
UNII IDQ461L7AK4R (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 161 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
47,726 adverse events reported
View more details